AbCellera Biologics Inc. Common Shares

ABCLNASDAQ • USD
12.08 USD
↗ 0.26 (2.20%)AT CLOSE (03:59 PM EDT)
12.01
↘ 0.07 (0.56%)
POST MARKET (AS OF 07:50 PM EDT)
Post Market
AS OF 07:50 PM EDT
12.01
↘ 0.07 (0.56%)
🔴Market: CLOSED

AbCellera Biologics Inc. Common Shares (ABCL) trades at $12.07 per share. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Oct 26, 2026.

Open?$12.02
High?$12.42
Low?$11.78
Prev. Close?$11.82
Volume?3.0M
Avg. Volume?5.1M
VWAP?$12.13
Rel. Volume?0.60x
Bid / Ask
Bid?$10.50 × 100
Ask?$13.80 × 100
Spread?$3.30
Midpoint?$12.15
Valuation & Ratios
Market Cap?3.8B
Shares Out?306.6M
Float?212.8M
Float %?69.4%
P/E Ratio?N/A
P/B Ratio?4.27
EPS?-$0.51
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Employees
562
Market Cap
3.8B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2020-12-11
Address
150 W 4TH AVENUE
VANCOUVER, A1 V5Y 1G6
Phone: (604) 559-9005
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
99
Momentum?
3
Short Sent.?
40
Piotroski F-Score?1/9Weak
Altman Z-Score?5.50Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?14.54%High
Short Interest?30.9M
Days to Cover?5.6
Free Float212.8M
Avg Daily Volume5.5M
Settlement Date2026-10-15
Financial Health
Current Ratio?12.77Strong
Quick Ratio?12.77Strong
Cash Ratio?2.26Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
42
4.27FAIR▾
P/S?
Peers
100
S&P
3
57.88HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-18.1CHEAP▾
EV/Sales?
Peers
100
S&P
3
56.07HIGH▾
Returns & Efficiency
ROE?
S&P
8
-18.4%WEAK▾
ROA?
S&P
3
-12.6%WEAK▾
Cash Flow & Enterprise
FCF?$-119671000
Enterprise Value?$3.7B
Fundamentals ratios updated end of day